Baird Reiterates an 'Outperform' on Incyte (INCY) following Confirmatory Phase 3 Details for Ruxolitinib
Go back to Baird Reiterates an 'Outperform' on Incyte (INCY) following Confirmatory Phase 3 Details for Ruxolitinib| Incyte Genomics, Inc. (NASDAQ: INCY) | Delayed: 120.16 -0.36 (0.3%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $120.52 | 52 Week High | $118.49 | |||
| Open | $119.15 | 52 Week Low | $55.00 | |||
| Day High | $120.44 | P/E | N/A | |||
| Day Low | $117.56 | EPS | $-0.56 | |||
| Volume | 785,829 | |||||
